Search clinical trials for: HLX03

Total 135 results

Shanghai Henlius Biotech

Not yet recruiting

A Study to Explore the Reasonable Dosage and Evaluate the Efficacy, Safety and Tolerability of HLX10 and HLX04 With or Without HLX53 in Untreated, Locally Advanced or Metastatic Hepatocellular Carcinoma Patients.

Carcinoma, Hepatocellular
Shanghai Henlius Biotech

Not yet recruiting

HLX07 Combination Therapy or Motherapy in Patient With Advanced Hepatocellular Carcinoma

Advanced Hepatocellular Carcinoma
Shanghai Henlius Biotech

Active, not recruiting

A Phase I Clinical Study of HLX53 in Advanced/Metastatic Solid Tumors

Advanced/Metastatic Solid Tumors

China
Shanghai Henlius Biotech

Recruiting

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

ESCC or Esophageal Adenosquamous Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors

Head and Neck Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study Evaluating the Use of HLX10 in Combination With HLX04 for the Treatment of Advanced Hepatocellular Carcinoma (HCC) Patients

Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Withdrawn

A Phase 1 Study of the CD73 Inhibitor(HLX23) Alone in Participants With Solid Tumor

Advanced Solid Tumor

United States
Shanghai Henlius Biotech

Recruiting

A Study of HLX07 + HLX10 With or Without Chemotherapy Versus HLX10 With Chemotherapy in First Line sqNSCLC

Squamous Non-small-cell Lung Cancer

China
Shanghai Henlius Biotech

Unknown

A Phase I Clinical Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Anti-PD-1 Antibody (HLX10) in Combination With Avastin Biosimilar (HLX04) in Patients With Advanced Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Completed

Study of Efficacy and Safety of HLX03 in Subjects With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
Shanghai Henlius Biotech

Completed

Phase I Study of HLX3 vs Adalimumab in Chinese Healthy Subjects

Immune System Disorder

China
Shanghai Henlius Biotech

Completed

A Study to Evaluate Safety, Tolerability, PK and PD of HLX01 in Patients With CD20-positive B-cell Lymphomas

B-cell Lymphomas
Shanghai Henlius Biotech

Completed

A Randomised, Double-blind, Phase I/II Study to Evaluate the PK, PD, Safety, and Efficacy Between HLX01 and Rituximab in Patients With Moderate to Severe Rheumatoid Arthritis and Inadequate Response to Treatment With DMARDs

Rheumatoid Arthritis
Shanghai Henlius Biotech

Recruiting

Phase II Clinical Study to Compare the Efficacy and Safety of HLX07 + Serplulimab +Chemotherapy Versus Placebo + Serplulimab + Chemotherapy in First-Line Treatment of Patients With Recurrent or Metastatic NPC

Nasopharyngeal Carcinoma by AJCC V8 Stage

China
Shanghai Henlius Biotech

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression

HLX07, nsqNSCLC, High EGFR Expression

China
Shanghai Henlius Biotech

Recruiting

HLX07+HLX10+Chemotherapy or HLX07 Monotherapy in Patients With Advanced Metastatic Gastric Cancer

Gastric Cancer (GC) Gastroesophageal Junction Cancer (GEJ)

China
Shanghai Henlius Biotech

Withdrawn

A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC

Hepatocellular Carcinoma (HCC)

China
Shanghai Henlius Biotech

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, and PK of HLX43 in Advanced/Metastatic Solid Tumors

Advanced Solid Tumor

China
Shanghai Henlius Biotech

Not yet recruiting

Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07+HLX10 +mFOLFOX6 or HLX07 Monotherapy in Patients With mCRC

CRC
Henlix, Inc

Terminated

A Study of HLX06, a Humanized Monoclonal Antibody Targeting Human Vascular Endothelial Growth Factor Receptor-2 in Patients With Advanced Solid Tumors

Solid Tumor, Adult

Taiwan
Shanghai Henlius Biotech

Recruiting

The Efficacy and Safety of HLX07 in Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma

China
Shanghai Henlius Biotech

Not yet recruiting

HLX07(Anti-EGFR mAb) in Patients With Advanced or Metastatic Solid Tumors

Solid Tumor

China
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(U.S. and German Sourced) in Healthy Chinese Male Subjects

Healthy

China
Henan Cancer Hospital

Recruiting

Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure

Non-Squamous Non-Small Cell Lung Cancer

China
Shanghai Henlius Biotech

Completed

A Pharmacokinetic and Pharmacodynamic Study Comparing HLX01 And Rituximab in Patients With CD20-Positive, B-cell Lymphoma

B-cell Non Hodgkin's Lymphoma
Shanghai Henlius Biotech

Active, not recruiting

A Phase 3 Study to Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

United States, Singapore, Spain, Germany, Slovakia, China, Hungary, Australia, Bulgaria, Poland, Latvia, Czechia, France, Italy, Serbia
Shanghai Henlius Biotech

Completed

Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

B-cell Non Hodgkin's Lymphoma

China
CHENNAN
Third Affiliated Hospital, Sun Yat-Sen University; Sir Run Run Shaw Hospital; Shanghai Pudong New Area People's Hospital and other collaborators

Recruiting

Rituximab and RASi in Patients With IgAN (RITA)

IgA Nephropathy

China
Shanghai Henlius Biotech

Withdrawn

Evaluate the Efficacy and Safety of HLX01 Versus Mabthera in Patients With Low Tumour Burden Follicular Lymphoma.

CD20-positive Follicular Lymphoma, With Low Tumour Burden
Shanghai Henlius Biotech

Completed

A Safety and Pharmacokinetic Study Between HLX02 and Herceptin®(US-licensed and EU-approved) in Healthy Chinese Male Subjects

Healthy

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC)

Metastatic Colorectal Cancer

China
Shanghai Henlius Biotech

Completed

The Safety,Efficacy of Anti-EGFR Humanized Monoclonal Antibody Combined With Chemotherapy in Advanced Solid Tumors. (HLX07Ib/II)

Advanced Solid Tumors

China
Tianjin Medical University Cancer Institute and...

Recruiting

Serplulimab Combined With Bevacizumab Biosimilar and HAIC in Advanced Hepatocellular Carcinoma (HCC) Patients

Advanced Hepatocellular Carcinoma

China
Shanghai Henlius Biotech

Completed

Compare Efficacy, Safety and Immunogenicity of HLX02 and Herceptin in Previously Untreated HER2 +Overexpressing Metastatic Breast Cancer

Breast Cancer

China
Shanghai Henlius Biotech

Not yet recruiting

A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer

Small-cell Lung Cancer

China
Shanghai Zhongshan Hospital
Shanghai Henlius Biotech

Not yet recruiting

Combination Therapy of HAIC and HLX10 and HLX04 in HCC With Major Portal Vein Tumor Thrombosis

Hepatocellular Carcinoma With Major Portal Vein Thrombosis
Shanghai Henlius Biotech

Recruiting

A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male Subjects

Healthy Male Volunteers

China
Huiqiang Huang

Recruiting

Rituximab and Pegylated Interferon α-2b in Patients With Indolent B-cell Lymphoma (RIPPLE)

Lymphoma, B-Cell

China
Shanghai Henlius Biotech

Completed

Pharmacokinetic, Safety and Immunogenicity Phase I Study of HLX04 Versus Avastin® in Healthy Male Subjects

Healthy Male Subjects

China
Shanghai Henlius Biotech

Active, not recruiting

A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC

Metastatic Colorectal Cancer (mCRC)

China
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy

Breast Ductal Carcinoma In Situ

United States, Canada, Puerto Rico, Korea, Republic of
Shanghai Henlius Biotech

Completed

Study of Safety and Efficacy of HLX01+MTX in Patients With Rheumatoid Arthritis

Moderately to Severely Active Rheumatoid Arthritis

China
Shanghai Henlius Biotech

Recruiting

Compare the Efficacy and Safety of HLX04-O With Ranibizumab in Subjects With wAMD

Age Related Macular Degeneration

China
Veana Therapeutics
University of Washington

Recruiting

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | HER2 Positive Breast Carcinoma | Metastatic Breast Carcinoma | Refractory Breast Carcinoma

United States
Children's Hospital of Fudan University
Shanghai Children's Hospital; Shanghai Children's Medical Center; Xinhua Hospital...

Withdrawn

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Steroid-Dependent Nephrotic Syndrome | Frequently Relapsing Nephrotic Syndrome

China
National Cancer Institute (NCI)
Gynecologic Oncology Group

Completed

Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Adenocarcinoma | Stage III Uterine Corpus Cancer AJCC v7 | Stage IV Uterine Corpus Cancer AJCC v7 | ERBB2 Gene Amplification

United States
Shanghai Henlius Biotech

Active, not recruiting

A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Carcinoma | Non-Small-Cell Lung

China
Indiana University School of Medicine

Completed

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

Glaucoma | Cataract

United States
National Cancer Institute (NCI)

Active, not recruiting

Paclitaxel and Trastuzumab With or Without Lapatinib in Treating Patients With Stage II or Stage III Breast Cancer That Can Be Removed by Surgery

Male Breast Carcinoma | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States, Puerto Rico
Jonsson Comprehensive Cancer Center
Eli Lilly and Company; Genentech, Inc.

Recruiting

Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer

Metastatic Lung Non-Small Cell Carcinoma | Refractory Lung Non-Small Cell Carcinoma | Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8 | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8

United States

3

Subscribe